• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Vaccine Market by Technology, Type, End User, Disease Indication - Forecasts to 2019 - Product Image

Vaccine Market by Technology, Type, End User, Disease Indication - Forecasts to 2019

  • ID: 2623206
  • January 2015
  • Region: Global
  • 211 Pages
  • Markets and Markets
The vaccine technology market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%.

FEATURED COMPANIES

  • Bavarian Nordic
  • CSL Limited
  • Glaxosmithkline, PLC.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • MORE

Vaccine Market by Technology (Live Attenuated, Toxoid, Conjugate, Subunit, Synthetic, Dendritic Cell, Inactivated), Type (Preventive, Therapeutic), End User (Pediatrics, Adults), Disease Indication (Infectious Disease, Cancer, Allergy) - Forecasts to 2019

The vaccines market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%. For the purposes of this report the global vaccines market is categorized on the basis of type, technology, disease indication, end user, and geography. The preventive vaccines segment is expected to register the highest growth rate in the vaccines market, by type, during the forecast period. Its favorable growth is attributed to the rising prevalence of diseases and increasing number of government initiatives taken for immunization programs worldwide.

Major factors contributing to growth of the vaccines market include rising prevalence of diseases, increasing company investments in vaccine development, and rising initiatives by non-government organizations for vaccinations. Furthermore, government support in the form of funding is another major factor providing impetus for growth of this market. For READ MORE >

Note: Product cover images may vary from those shown
The vaccine technology market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%.

FEATURED COMPANIES

  • Bavarian Nordic
  • CSL Limited
  • Glaxosmithkline, PLC.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • MORE

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology
2.1 Market Size Estimation
2.2 Market Breakdown and Data Triangulation
2.3 Market Share Estimation
2.4 Key Data From Secondary Sources
2.5 Key Data From Primary Sources
2.6 Key Industry Insights
2.7 Assumptions

3 Executive Summary

4 Premium Insights
4.1 Vaccine Technology Market to Have High Growth Potential
4.2 Global Vaccine Technology Market, By Type
4.3 Global Vaccine Technology Market, By Region
4.4 Vaccine Technology Market, By Disease Indication
4.5 Global Vaccine Technology Market, By End Users
4.6 Lifecycle Analysis, By Region

5 Market Overview
5.1 Introduction
5.2 Market Segmentation
5.2.1 By Type
5.2.2 By Disease Indication
5.2.3 By End User
5.2.4 By Region
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 High Prevalence of Diseases
5.3.1.2 Rising Government and Non-Government Funding for Vaccine Development
5.3.1.3 Increasing Investments By Companies
5.3.1.4 Technological Advancements
5.3.2 Restraints
5.3.2.1 Huge Capital Investments
5.3.2.2 Stringent Regulatory Procedures
5.3.3 Opportunities
5.3.3.1 High Growth Prospects in Emerging Markets
5.3.3.2 Therapeutic Vaccines
5.3.3.3 Adjuvant Vaccines
5.3.4 Challenges
5.3.4.1 Inadequate Access to Vaccines
5.3.4.2 Vaccine Pricing
5.3.5 Burning Issues
5.3.5.1 Failure of Vaccines

6 Industry Insights
6.1 Porter’s Five Forces Analysis
6.1.1 Threat From New Entrants
6.1.2 Bargaining Power of Suppliers
6.1.3 Bargaining Power of Buyers
6.1.4 Intensity of Competitive Rivalry
6.1.5 Threat of Substitutes
6.2 Value Chain Analysis
6.3 Supply Chain Analysis
6.4 Technology Trends
6.4.1 Drivers
6.4.1.1 Increasing Use of Adjuvants in Vaccine-Preventable Diseases
6.4.1.2 Rising Government Investments
6.4.2 Restrains
6.4.2.1 High Cost of Research
6.4.2.2 Regulatory Hurdles
6.4.3 Opportunities
6.4.3.1 Combined Adjuvants
6.4.3.2 Vaccines for Young Children
6.4.3.3 Pandemic Diseases
6.4.4 Challenges
6.4.4.1 Identification of Adjuvants
6.4.4.2 Technological Limitations
6.4.5 Trends
6.4.5.1 Collaborations
6.4.5.2 New Adjuvant Technologies
6.5 Investment Analysis
6.6 Regulatory Landscape
6.6.1 North America
6.6.2 Europe
6.6.3 Asia
6.6.4 ROW
6.7 Patent Analysis
6.8 Key Pipeline Products
6.9 Strategic Benchmarking

7 Vaccines Market, By Technology
7.1 Subunit Vaccines
7.2 Live Attenuated Vaccines
7.3 Conjugate Vaccines
7.4 Inactivated Vaccines
7.5 Recombinant Vector Vaccines
7.6 Toxoid Vaccines
7.7 Synthetic Vaccines
7.8 Dendritic Cell Vaccines

8 Vaccines Market, By Type
8.1 Introduction
8.2 Preventive Vaccines
8.3 Therapeutic Vaccines

9 Vaccines Market, By Disease Indication
9.1 Introduction
9.2 Infectious Diseases
9.2.1 Pneumonia
9.2.2 Influenza
9.2.3 DTP
9.2.4 Hepatitis
9.2.5 Rotavirus
9.2.6 Varicella
9.2.7 Meningococcal
9.2.8 Polio
9.2.9 MMR
9.2.10 Others
9.3 Cancer
9.3.1 Cervical Cancer
9.3.2 Others
9.4 Allergies

10 Vaccines Market, By End User
10.1 Introduction
10.2 Pediatrics
10.3 Adults

11 Global Vaccine Technology Market, By Region
11.1 Introduction
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 France
11.3.3 U.K.
11.3.4 Italy
11.3.5 Spain
11.3.6 Rest of Europe (ROE)
11.4 Asia
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Rest of Asia (ROA)
11.5 Rest of the World (ROW)

12 Competitive Landscape
12.1 Overview
12.2 Market Share Analysis
12.3 Competitive Situation and Trends
12.3.1 Agreements, Collaborations & Partnerships
12.3.2 Regulatory Approvals
12.3.3 Acquisitions
12.3.4 Other Developments

13 Company Profiles
13.1 Glaxosmithkline, PLC.
13.1.1 Business Overview
13.1.2 Product Portfolio
13.1.3 Key Strategies
13.1.4 Recent Developments
13.1.5 MNM View
13.2 Merck & Co., Inc.
13.2.1 Business Overview
13.2.2 Product Portfolio
13.2.3 Key Strategy
13.2.4 Recent Developments
13.2.5 MNM View
13.3 SANOFI
13.3.1 Business Overview
13.3.2 Product Portfolio
13.3.3 Key Strategy
13.3.4 Recent Developments
13.3.5 MNM View
13.4 Pfizer, Inc.
13.4.1 Business Overview
13.4.2 Product Portfolio
13.4.3 Key Strategy
13.4.4 Recent Developments
13.4.5 MNM View
13.5 Novartis AG
13.5.1 Business Overview
13.5.2 Product Portfolio
13.5.3 Key Strategy
13.5.4 Recent Developments
13.5.5 MNM View
13.6 Bavarian Nordic
13.6.1 Business Overview
13.6.2 Product Portfolio
13.6.3 Key Strategy
13.6.4 Recent Developments
13.7 CSL Limited
13.7.1 Business Overview
13.7.2 Product Portfolio
13.7.3 Key Strategy
13.7.4 Recent Developments
13.8 Emergent Biosolutions, Inc.
13.8.1 Business Overview
13.8.2 Product Portfolio
13.8.3 Key Strategy
13.8.4 Recent Developments
13.9 Johnson & Johnson
13.9.1 Business Overview
13.9.2 Product Portfolio
13.9.3 Key Strategy
13.9.4 Recent Developments
13.10 Medimmune, LLC. (A Subsidiary of Astrazeneca)
13.10.1 Business Overview
13.10.2 Product Portfolio
13.10.3 Key Strategy
13.10.4 Recent Developments

14 Appendix
14.1 Insights From Industry Experts
14.2 Discussion Guide
14.3 Available Customizations
14.4 Related Reports
14.5 Introducing RT: Real-Time Market Intelligence

List of Tables (145 Tables)

Table 1 Increasing Prevalence of Diseases to Boost the Market Growth of Vaccines
Table 2 Huge Capital Investment to Limit the Market Growth of Vaccines
Table 3 Increasing Prevalence of Diseases to Boost the Market Growth of Vaccines
Table 4 Increasing Prevalence of Diseases to Boost the Market Growth of Vaccines
Table 1 National Institutes of Health (NIH) Funding for Vaccine Development, 2011–2013 ($Million)
Table 2 Regulatory Authorities in Europe
Table 3 Regulatory Authorities in Asia
Table 4 Key Pipeline Vaccines
Table 5 Vaccine Market Size, By Technology, 2012-2019 ($Million)
Table 6 Subunit Vaccine Market Size, By Region, 2012-2019 ($Million)
Table 7 North America: Subunit Vaccine Market Size, By Country, 2012-2019 ($Million)
Table 8 Europe: Subunit Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 9 Asia: Subunit Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 10 Live Attenuated Vaccines Market Size, By Region, 2012-2019 ($Million)
Table 11 North America: Live Attenuated Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 12 Europe: Live Attenuated Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 13 Asia: Live Attenuated Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 14 Conjugate Vaccines Market Size, By Region, 2012-2019 ($Million)
Table 15 North America: Conjugate Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 16 Europe: Conjugate Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 17 Asia: Conjugate Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 18 Inactivated Vaccines Market Size, By Region, 2012-2019 ($Million)
Table 19 North America: Inactivated Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 20 Europe: Inactivated Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 21 Asia: Inactivated Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 22 Recombinant Vector Vaccines Market Size, By Region, 2012-2019 ($Million)
Table 23 North America: Recombinant Vector Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 24 Europe: Recombinant Vector Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 25 Asia: Recombinant Vector Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 26 Toxoid Vaccines Market Size, By Region, 2012-2019 ($Million)
Table 27 North America: Toxoid Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 28 Europe: Toxoid Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 29 Asia: Toxoid Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 30 Synthetic Vaccines Market Size, By Region, 2012-2019 ($Million)
Table 31 North America: Synthetic Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 32 Europe: Synthetic Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 33 Asia: Synthetic Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 34 Dendritic Cell Vaccines Market Size, By Region, 2012-2019 ($Million)
Table 35 North America: Dendritic Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 36 Europe: Dendritic Cell Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 37 Asia: Dendritic Cell Vaccines Market Size, By Country, 2012-2019 ($Million)
Table 38 Vaccines Market Size, By Type, 2012–2019 ($Million)
Table 39 Preventive Vaccines Market Size, By Region, 2012–2019 ($Million)
Table 40 North America: Preventive Vaccines Market Size, By Country, 2012–2019 ($Million)
Table 41 Europe: Preventive Vaccines Market Size, By Country, 2012–2019 ($Million)
Table 42 Asia: Preventive Vaccines Market Size, By Country, 2012–2019 ($Million)
Table 43 Therapeutic Vaccines Market Size, By Region, 2012–2019 ($Million)
Table 44 North America: Therapeutic Vaccines Market Size, By Country, 2012–2019 ($Million)
Table 45 Europe: Therapeutic Vaccine Market Size, By Country, 2012–2019 ($Million)
Table 46 Asia: Therapeutic Vaccines Market Size, By Country, 2012–2019 ($Million)
Table 47 Vaccines Market Size, By Disease Indication, 2012–2019 ($Million)
Table 48 Vaccines Market Size for Infectious Diseases, By Region, 2012-2019 ($Million)
Table 49 North America: Vaccines Market Size for Infectious Diseases, By Country, 2012–2019 ($Million)
Table 50 Europe: Vaccine Technology Market Size for Infectious Diseases, By Country, 2012–2019 ($Million)
Table 51 Asia: Vaccine Technology Market Size for Infectious Diseases, By Country, 2012-2019 ($Million)
Table 52 Infectious Diseases Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
Table 53 Vaccine Technology Market Size for Cancer, By Region, 2012–2019 ($Million)
Table 54 North America: Vaccine Technology Market Size for Cancer, By Country, 2012–2019 ($Million)
Table 55 Europe: Vaccine Technology Market Size for Cancer, By Country, 2012–2019 ($Million)
Table 56 Asia: Vaccine Technology Market Size for Cancer, By Country, 2012–2019 ($Million)
Table 57 Cancer Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
Table 58 Vaccine Technology Market Size for Allergies, By Region, 2012–2019 ($Million)
Table 59 North America: Vaccine Technology Market Size for Allergies, By Country, 2012–2019 ($Million)
Table 60 Europe: Vaccine Technology Market Size for Allergies, By Country, 2012–2019 ($Million)
Table 61 Asia: Vaccine Technology Market Size for Allergies, By Country, 2012–2019 ($Million)
Table 62 Vaccine Technology Market Size, By End User, 2012–2019 ($Million)
Table 63 Vaccine Technology Market Size for Pediatrics, By Region, 2012–2019 ($Million)
Table 64 North America: Vaccine Technology Market Size for Pediatrics, By Country, 2012–2019 ($Million)
Table 65 Europe: Vaccine Technology Market Size for Pediatrics, By Country, 2012–2019 ($Million)
Table 66 Asia: Vaccine Technology Market Size for Pediatrics, By Country, 2012–2019 ($Million)
Table 67 Vaccine Technology Market Size for Adults, By Region, 2012–2019 ($Million)
Table 68 North America: Vaccine Technology Market Size for Adults, By Country, 2012–2019 ($Million)
Table 69 Europe: Vaccine Technology Market Size for Adults, By Country, 2012–2019 ($Million)
Table 70 Asia: Vaccine Technology Market Size for Adults, By Country, 2012–2019 ($Million)
Table 71 Vaccine Technology Market Size, By Region, 2012–2019 ($Million)
Table 72 North America: Vaccine Technology Market Size, By Country, 2012–2019 ($Million)
Table 73 Europe: Vaccine Technology Market Size, By Country, 2012–2019 ($Million)
Table 74 Asia: Vaccine Technology Market Size, By Country, 2012–2019 ($Million)
Table 75 North America: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
Table 76 North America: Market Size, By Type, 2012-2019 ($Million)
Table 77 North America: Size, Market By Disease Indication, 2012-2019 ($Million)
Table 78 North America: Market Size, By End Users, 2012-2019 ($Million)
Table 79 U.S.: Vaccine Market Size, By Technology, 2012-2019 ($Million)
Table 80 U.S.: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
Table 81 U.S.: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million)
Table 82 U.S.: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million)
Table 83 Canada: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
Table 84 Canada: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
Table 85 Canada: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million)
Table 86 Canada: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million)
Table 87 Europe: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
Table 88 Europe: Market Size, By Type, 2012-2019 ($Million)
Table 89 Europe: Market , By Disease Indication, 2012-2019 ($Million)
Table 90 Europe: Market Size, By End Users, 2012-2019 ($Million)
Table 91 Germany: Vaccines Technology Market Size, By Technology, 2012-2019 ($Million)
Table 92 Germany: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
Table 93 Germany: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million)
Table 94 Germany: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million)
Table 95 France: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
Table 96 France: Market Size, By Type, 2012-2019 ($Million)
Table 97 France: Market Size, By Disease Indication, 2012-2019 ($Million)
Table 98 France: Market Size, By End Users, 2012-2019 ($Million)
Table 99 U.K. : Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
Table 100 U.K.: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
Table 101 U.K.: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million)
Table 102 U.K.: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million)
Table 103 Italy: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
Table 104 Italy: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
Table 105 Italy: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million)
Table 106 Italy: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million)
Table 107 Spain: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
Table 108 Spain: Vaccines Market Size, By Type, 2012-2019 ($Million)
Table 109 Spain: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million)
Table 110 Spain: Market Size, By End Users, 2012-2019 ($Million)
Table 111 ROE: Market Size, By Technology, 2012-2019 ($Million)
Table 112 ROE: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
Table 113 ROE: Market Size, By Disease Indication, 2012-2019 ($Million)
Table 114 ROE: Market Size, By End Users, 2012-2019 ($Million)
Table 115 Asia: Vaccines Technology Market Size, By Technology, 2012-2019 ($Million)
Table 116 Asia: Market Size, By Type, 2012-2019 ($Million)
Table 117 Asia: Market Size, By Disease Indication, 2012-2019 ($Million)
Table 118 Asia: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million)
Table 119 Japan: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
Table 120 Japan: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
Table 121 Japan: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million)
Table 122 Japan: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million)
Table 123 China: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
Table 124 China: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
Table 125 China: Market Size, By Disease Indication, 2012-2019 ($Million)
Table 126 China: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million)
Table 127 India: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
Table 128 India: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
Table 129 India: Vaccine Technology Market Size, By Disease Indication, 2012-2019 ($Million)
Table 130 India: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million)
Table 131 ROA: Vaccine Technology Market Size, By Technology, 2012-2019 ($Million)
Table 132 ROA: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
Table 133 ROA: Market Size, By Disease Indication, 2012-2019 ($Million)
Table 134 ROA: Market Size, By End Users, 2012-2019 ($Million)
Table 135 ROW: Market Size, By Technology, 2012-2019 ($Million)
Table 136 ROW: Vaccine Technology Market Size, By Type, 2012-2019 ($Million)
Table 137 ROW: Market Size, By Disease Indication, 2012-2019 ($Million)
Table 138 ROW: Vaccine Technology Market Size, By End Users, 2012-2019 ($Million)
Table 139 Recent Agreements and Collaborations
Table 140 Recent Regulatory Approvals
Table 141 Recent Acquisitions
Table 142 Recent Other Developments
Table 143 Exchange Rates (Utilized for Conversion of GBP to USD)
Table 144 Exchange Rates (Utilized for Conversion of EURO to USD)
Table 145 Exchange Rates (Utilized for the Conversion of DKK to USD)

List of Figures (65 Figures)

Figure 1 Vaccines Market, By Technology
Figure 2 Research Methodology
Figure 3 Top-Down Approach
Figure 4 Bottom-Up Approach
Figure 5 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 6 Data Triangulation Methodology
Figure 7 Vaccine Technology Market Snapshot (2014 vs. 2019): Sub-Unit Vaccines to Grow at Highest CAGR
Figure 8 Preventive Vaccines to Dominate the Vaccines Market
Figure 9 Pediatric Segment Will Be the Largest End-User Segment in the Vaccines Market
Figure 10 North America to Hold Largest Share in the Global Vaccines Market
Figure 11 Market Growth Will Be Driven By Prevalence of Diseases
Figure 12 Preventive Vaccines Segment Held the Largest Share in Vaccines Market, By Type
Figure 13 U.S. Commands One-Third of the Market
Figure 14 Infectious Diseases Segment Has A Promising Future in Emerging Economies
Figure 15 Pediatrics Segment Will Continue to Lead the Vaccines End-Users Market During the Forecast Period
Figure 16 Asia to Witness High Growth Rate in the Vaccines Market During Forecast Period
Figure 17 Vaccines Market Segmentation: By Type
Figure 18 Vaccines Market Segmentation: By Disease Indication
Figure 19 Vaccines Market Segmentation: By End User
Figure 20 Vaccines Market Segmentation: By Region
Figure 21 Increasing Government Support for Pandemic Threats Likely to Fuel Growth of Vaccines Market
Figure 22 Porter’s Five Forces Analysis
Figure 23 Value Chain Analysis: Major Value is Added During the Development and Manufacturing Phases
Figure 24 Supply Chain Analysis
Figure 25 Cold Chain Management
Figure 26 FDA-Approved Vaccine Adjuvants
Figure 27 Licensed Vaccines Containing Adjuvants
Figure 28 Examples of Vaccine Adjuvants in Clinical Trials
Figure 29 Investors Play an Important Role in the Vaccines Market
Figure 30 Vaccine Research Funding, By Type of Investor
Figure 31 U.S. Government Agencies Held Largest Share of the HIV R&D Funding in 2013
Figure 32 Regulatory Approval Process for Vaccines
Figure 33 North America Accounted for the Largest Number of Patent Filings in 2012
Figure 34 The U.S. Accounted for Largest Number of Patent Filings Across the Globe (2012)
Figure 35 Strategic Benchmarking: Glaxosmithkline, PLC. Largely Adopted Inorganic Growth Strategies for Enhancing Product Offerings
Figure 36 Subunit Vaccines Segment to Grow at Highest CAGR in Forecast Period
Figure 37 North America to Dominate the Inactivated Vaccines Market From 2014 to 2019
Figure 38 Toxoid Vaccines Market in Asia Will Grow at Highest CAGR From 2014 to 2019
Figure 39 Reference Figure
Figure 40 Preventive Vaccines to Dominate the Global Vaccines Market From 2014 to 2019
Figure 41 Asia to Grow at the Highest CAGR From 2014 to 2019
Figure 42 Infectious Diseases Segment to Dominate the Vaccines Market From 2014 to 2019
Figure 43 The Pediatrics End-User Segment Will Drive the Vaccines Market During the Forecast Period
Figure 44 Geographic Snapshot (2014): Emerging Markets Hold Growth Opportunities
Figure 45 Geographic Benchmarking for Vaccine Technology Market
Figure 46 Market Growth Will Be Driven By Increasing R&D Activities for Development of Vaccines
Figure 47 Infectious Diseases Segment Will Continue to Drive the Vaccines Market
Figure 48 Germany Will Continue to Dominate the Vaccines Market in Europe
Figure 49 German Vaccines Market to Grow at the Highest CAGR in Europe
Figure 50 Asia Will Grow at the Highest CAGR in the Vaccines Market
Figure 51 Indian Vaccines Market Will Have High Growth Potential
Figure 52 Preventive Vaccines Will Lead the Vaccines Market of ROW in 2019
Figure 53 Major Players Signed Agreements to Enhance Their Market Positions in the Vaccines Market
Figure 54 Global Vaccines Market Share, By Key Player, 2013
Figure 55 Battle for Market Share: Agreements Was the Key Strategy Adopted By Market Players
Figure 56 Glaxosmithkline, PLC.: Company Snapshot
Figure 57 Merck & Co., Inc.: Company Snapshot
Figure 58 SANOFI: Company Snapshot
Figure 59 Pfizer Inc.: Company Snapshot
Figure 60 Novartis AG: Company Snapshot
Figure 61 Bavarian Nordic: Company Snapshot
Figure 62 CSL Limited: Company Snapshot
Figure 63 Emergent Biosolutions: Company Snapshot
Figure 64 Johnson & Johnson: Company Snapshot
Figure 65 Astrazeneca : Company Snapshot

Note: Product cover images may vary from those shown
The vaccine technology market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%.

FEATURED COMPANIES

  • Bavarian Nordic
  • CSL Limited
  • Glaxosmithkline, PLC.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • MORE

The global vaccine technology market involves different human vaccines that help in the prevention and treatment of diseases such as cholera, typhoid, and influenza. Vaccine technology market is driven by several factors which include high prevalence of diseases, increasing government initiatives for expanding immunization across the globe, increasing company investments in vaccine development, and rising initiatives by non-government organizations for vaccinations. The emerging market and increasing vaccine research have opened an array of opportunities for growth of the market. However, low accessibility to vaccines in remote areas and stringent regulatory procedures are expected to restrain the growth of market.

The vaccine technology market by type is divided into preventive and therapeutic vaccines. Preventive vaccines accounted for the largest share of the market primarily due to the increasing prevalence of infectious diseases. In addition, increasing investments by government and non-government organizations to enhance vaccine research and supply doses worldwide will further enhance the growth of market.

On the basis of technologies, the vaccines market is classified into live attenuated, toxoid, conjugate, subunit, recombinant vector, inactivated, synthetic, and dendritic cell vaccines. The subunit vaccines segment accounted for the largest share of the market. Increasing research activities for development of more effective and safe vaccines will drive the growth of market.

The disease indication vaccine technology market is segmented into infectious diseases, cancer, and allergy. The infectious diseases segment accounted for a major share of market. Growth in this segment can be attributed to the high prevalence of infectious diseases and increasing government initiatives to improve immunization programs across the globe. The infectious diseases segment is further categorized into pneumococcal, influenza, DTP, hepatitis, rotavirus, varicella, meningococcal, polio, MMR and others. The cancer segment is classified as cervical cancer and others.

On the basis of end users, the vaccine technology market is segmented into pediatrics and adults. Pediatrics is the major end user of market. High prevalence of diseases such as tuberculosis, mumps, and meningitis will boost the growth of this segment.

The global market is dominated by North America, followed by Europe, Asia, and Rest of the World (RoW). North America will continue to lead the global market in the forecast period. However, Asia is expected to be the fastest-growing market, with growth centered on China, India, and Japan.

Key players in the vaccine technology market include Bavarian Nordic (Denmark), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), GlaxoSmithKline, plc. (U.K.), Johnson and Johnson (U.S.), MedImmune, LLC (U.S.), Merck and Company (U.S.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), and Sanofi Pasteur (France).

Note: Product cover images may vary from those shown
The vaccine technology market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%.

- Bavarian Nordic
- CSL Limited
- Emergent Biosolutions, Inc.
- Glaxosmithkline, PLC.
- Johnson & Johnson
- Medimmune, LLC. (A Subsidiary of Astrazeneca)
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- SANOFI

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Pfizer, Inc. Grünenthal GmbH GlaxoSmithKline PLC Abbott Laboratories Ltd. Roche Diagnostics Ltd. Novo Nordisk A/S